Webinar: Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model by InsideScientific

Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model

About

Understanding aldehyde oxidase (AO)-mediated metabolism has become increasingly critical in drug development, as traditional models often fail to capture this non-CYP clearance pathway with sufficient accuracy. In this exclusive session, Stephanie Piekos, PhD, Senior Scientist at Boehringer Ingelheim, shares insights into the challenges of evaluating AO substrates and how more predictive, human-relevant models are shaping the future of DMPK studies.

Join us to explore how TruVivo®—LifeNet Health’s all-human 2D+ hepatic system—delivers enhanced AO activity compared to conventional in vitro models. With improved enzyme stability and metabolic function over extended culture periods, TruVivo offers a powerful platform for identifying metabolic liabilities, predicting human clearance, and bridging translational gaps in early development. This session is a must for scientists focused on advancing preclinical models for more accurate and reliable decision-making.

Key Topics:

Understand the metabolic role and clinical importance of aldehyde oxidase

Recognize the limitations of traditional models for studying AO-mediated clearance

Discover how TruVivo enhances AO activity to support more predictive, human-relevant outcomes

Presenter

Stephanie Piekos, PhD

Principal Scientist, Nonclinical Drug Metabolism and Pharmacokinetics Group, Boehringer Ingelheim

Stephanie is currently a Principal Scientist in the Nonclinical Drug Metabolism and Pharmacokinetics group at Boehringer Ingelheim in Ridgefield, Connecticut. Her group focuses on characterizing the metabolism and drug-drug interaction potential of small molecules in the development pipeline using in vitro tools. Stephanie joined Boehringer seven years ago after completing her Ph.D. in Pharmaceutical Sciences at the University of Connecticut School of Pharmacy, where her research efforts involved understanding the impact of postnatal antiepileptic drug exposure on CYP-mediated metabolism and enzyme induction.

First Name*

Last Name*

Email Address*

Organization / Company*

Organization Type*

Job Title*

Country / Region*

Main Application Areas*

ADME/DMPK

Toxicology

Assay Development

Agrichemicals

Antibody Drug Candidates

Nanoparticles

Other

What systems are you currently using (check all that apply)?*

Human primary hepatocytes

Animal primary hepatocytes

Cell lines (ex. HepG2 or Huh-7)

Pooled hepatocytes

Spheroids

Co-cultures

What plate format do you prefer to use most often?*

utm_bmcr_source